KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCash from Discontinued OperationsCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Long-Term Debt Repayments (2021 - 2022)

TherapeuticsMD (TXMD) has disclosed Long-Term Debt Repayments for 5 consecutive years, with $94.4 million as the latest value for Q4 2022.

  • For the quarter ending Q4 2022, Long-Term Debt Repayments changed N/A year-over-year to $94.4 million, compared with a TTM value of $334.4 million through Dec 2022, up 568.86%, and an annual FY2022 reading of $219.4 million, up 338.86% over the prior year.
  • Long-Term Debt Repayments was $94.4 million for Q4 2022 at TherapeuticsMD, down from $120.0 million in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $120.0 million in Q1 2022 and bottomed at $50.0 million in Q1 2021.